Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer

Adagene (NASDAQ:ADAG) anticipates Phase II data for its CTLA-4 therapy in MSS colorectal cancer, aiming to replicate Phase Ib response rates of 17-25%. The company plans FDA meetings post-Phase II and potential Phase III trials. Adagene also has a neoadjuvant study in Singapore, with results expected in 2027. It collaborates with Incyte on a combination therapy and has a cash runway into 2028.

Original reporting
Published Oct 25, 2026, 10:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 25, 2026, 10:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer — source image
Decision brief

The 30-second read

$ADAGNeutralLow
01

Why it matters

The announcement of Phase II plans and cash runway provides new information for valuation models but does not create an immediate trade trigger.

02

Market read

Provides early insight into upcoming trial data and financial runway, useful for biotech-focused investors.

03

What to watch

Potential competition from other CTLA-4 or bispecific programs and regulatory timelines.

Relevance 5/10Novelty 7/10Timing: future outlook, data expected in 2027

Background

Adagene (NASDAQ:ADAG) is a clinical‑stage biotech developing masked antibody therapies. The company recently raised cash in a follow‑on offering.

Company-level read

Ticker impact

$ADAGNeutralMedium confidence
Context

Adagene announced plans to generate Phase II data for its masked CTLA-4 therapy ADG126 in MSS colorectal cancer and disclosed a cash runway into H2 2028.

Expected impact

potential upside if Phase II results are favorable, otherwise pressure from uncertainty

Evidence & confidence

The article provides first‑report details on upcoming trial milestones and cash resources, but no concrete results yet.

Market effects

May influence investor sentiment toward early‑stage immunotherapy biotech peers.

Limited to US‑listed biotech sector.

Low global impact; primarily relevant to specialty biotech investors.

Counterpoint

Investors could short on the basis that the trial may fail and cash burn could become a concern.

Key entities

  • Adagene Inc.

    Clinical‑stage biopharma developing masked CTLA-4 therapy ADG126.

  • Incyte

    Partner in a PD‑1/TIGIT bispecific collaboration with Adagene.

Related articles

$ADAGLowAI 8/10

Adagene completes enrollment in phase 2 trial of muzastotug

Adagene Inc. (ADAG) completed enrollment in a Phase 2 trial of muzastotug, an anti-CTLA-4 antibody therapy, combined with Merck’s KEYTRUDA for late-line colorectal cancer. The trial enrolled 60 patients, with results expected in early 2027. The FDA confirmed Phase 3 trial design elements, and Sanofi invested in the trial. Muzastotug has FDA Fast Track designation.